Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.40 |
| ▸ | NT5E | P21589 | 2/20 | 0.40 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
| ▸ | HPGDS | O60760 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20967320 | 0.96 | TOP1 (0.42) | TAAR1DPP4ESR2ABCG2ABCC1 | |
| SCHEMBL20967338 | 0.94 | TAAR1 (0.45) | TAAR1DPP4ESR2ABCG2NT5E | |
| SCHEMBL20967349 | 0.91 | TOP1 (0.43) | DPP4ABCG2CYP3A4 | |
| SCHEMBL20967381 | 0.91 | ABCG2 (0.43) | TAAR1DPP4ESR2ABCG2ABCC1 | |
| SCHEMBL20967398 | 0.91 | TAAR1 (0.39) | TAAR1DPP4ESR2ABCG2 | |
| SCHEMBL20967426 | 0.91 | TOP1 (0.44) | DPP4ABCG2 | |
| SCHEMBL20967400 | 0.91 | TOP1 (0.44) | DPP4ABCG2 | |
| SCHEMBL20967448 | 0.91 | TOP1 (0.44) | DPP4ABCG2CYP3A4 | |
| SCHEMBL20967450 | 0.91 | TOP1 (0.44) | DPP4ABCG2CYP3A4 | |
| SCHEMBL20967346 | 0.91 | TOP1 (0.44) | DPP4ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11251376-B2 | Heterocyclic compound and organic light-emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2022-02-15 | — | — | US | disclosed |
| US-20190131535-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11251376-B2 | Heterocyclic compound and organic light-emitting device including the same | LAGE3, DDT, AOC2 | TAAR1 2337/4885DPP4 2961/4885ESR2 186/4885 |
| US-20190131535-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | LAGE3, DDT, AOC2 | TAAR1 2337/4885DPP4 2961/4885ESR2 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.